# Vaccines and antibodies for arenaviruses

> **NIH NIH U19** · VANDERBILT UNIVERSITY MEDICAL CENTER · 2024 · $7,023,024

## Abstract

PROJECT SUMMARY - RP5
Arenaviruses, a family of viruses with pandemic potential, can cause hemorrhagic fever, meningitis, and other
clinical syndromes. These viruses include highly pathogenic strains such as Lassa virus (LASV) and Junín
virus (JUNV), as well as less pathogenic strains like lymphocytic choriomeningitis virus (LCMV). In this project,
we aim to focus on two major areas, active immunity induced by experimental vaccines and passive immunity
conferred by injection with human monoclonal antibodies. The later studies will include the study of extended
half-life protective antibodies bearing Fc mutations that cause ≥90-day half-life profiles in humans and thus
enable a vaccine-like prophylactic profile of a year or more. First, in studies in Aim 1, we will compare leading
vaccine platform technologies and define immune correlates of protection for LCMV in nonhuman primate
models of infection (macaques) as a virus prototype. Understanding the principles of immunity to this prototype
virus will allow us then to pivot and use those mechanistic insights to design and test vaccines for other
arenaviruses. This work will allow us to fully explore replicating attenuated LCMV vectors as a strategy for
developing candidate arenavirus vaccines. We also will explore the hypothesis that both antibodies and T cell
responses contribute to vaccine -induced protection against LCMV. Next, in studies in Aim 2, we will focus on
deploying optimal vaccine strategies for other arenaviruses of pandemic concerns, LASV and JUNV. Lastly, in
work in Aim 3, we will identify and characterize fully human neutralizing monoclonal antibodies and their
epitope targets, with initial work in LCMV antibody discovery providing a platform for further work on other
medically important arenaviruses. This project will be synergistic with other projects in the BP4 center focusing
on picornavirus and hantavirus vaccines and with the BP4 human monoclonal antibody projects to develop
candidate arenavirus, picornavirus, and hantavirus medical countermeasures.

## Key facts

- **NIH application ID:** 10863663
- **Project number:** 1U19AI181979-01
- **Recipient organization:** VANDERBILT UNIVERSITY MEDICAL CENTER
- **Principal Investigator:** ROBERT H CARNAHAN
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $7,023,024
- **Award type:** 1
- **Project period:** 2024-08-20 → 2027-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10863663

## Citation

> US National Institutes of Health, RePORTER application 10863663, Vaccines and antibodies for arenaviruses (1U19AI181979-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10863663. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*